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Temporary interruption of treatment in three patients is not a high 
rate of pauses that may affect the outcome of cancer treatment (local 
control of the disease). It also shows the small negative effect of 
these treatments during application and good clinical acceptance in 
groups of elderly patients. Definitive interruption of treatment 
occurred in only 2 patients. They were not as a result of acute toxicity 
produced during radiotherpay, which reaffirms the option of external 
radiation therapy as a treatment in elderly based on toxicity criteria 
and/or fragility of the patient.Hypofractionation may be a valid 
treatment regimen in elderly patients with comorbidities. 
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Purpose/Objective: To compare orthovoltage X-ray therapy (OXRT) 
and standard treatment for reducing pain in knee OA.  
Materials and Methods: Twentyone patients having Grade 1 of knee 
joints OA evaluated by Kellgren Lawrence Score, were prospectively 
randomized to OXRT (n=11) or standard treatment consisting of 
combined Chondroitin (CS) and Glucosamine Sulfates (GS) medicine 
'Theraflex' and non-steroid anti-inflammatory drug Ketoprofen (n=10). 
Dose prescription for OXRT (XStrahl-200, Gulmay Medical Inc., USA) 
was 4,8 Gy in 10 fractions for 3.5 weeks. Theraflex was given 1 dose, 
containing CS 400 mg and GS 500 mg 3 times per day during 3 weeks in 
combination with Ketoprofen 100 mg 3 times a day. Supportive 
treatment consisting of Theraflex twice daily and Ketoprofen 100 mg 
up to 2 times a day begun from the fourth week during 3 months. The 
pain severity was evaluated by visual-analogue scale (VAS). The 
comparative analysis, considering the values in VAS being continuous, 
was performed using Mann-Whitney test. 
Results: Median age of patients in OXRT group was 53.2 (SD, 2.80) and 
Theraflex group 55.1 (SD,3.2). The proportions of males were 45.5% 
and 40.0% for OXRT and Theraflex groups respectively. The 
distribution on initial characteristics was equal. Initially, the pain 
severity in OXRT group was 7.3 (95% CI, 6.6-7.9) and 7.5 (95% CI, 6.8-
8.3) for the patients of Theraflex group. After 3 months of follow-up 
the pain level by VAS has been reduced by 4,3 (Q1 3.0 - Q3 5.6) and 
2,4(Q1 0.6 - Q3 3.3), ?=0.006, U=17.00 among patients of OXRT and 
Theraflex groups, respectively. 
Conclusions: Orthovoltage X-ray therapy allows decreasing 
significantly pain after 3 month. The evolution of cartilage thickness 
and long-term safety should be measured further.  
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Purpose/Objective: To assess the efficacy and safety of neoadjuvant 
chemoradiotherapy in elderly patients with resectable oesophageal 
carcinoma by a systematic review. 
Materials and Methods: Medline, Embase, ISI Web of Knowledge, 
Cochrane Library and China Biological Medicine Database were 
systematically searched in September 2012. Studies comparing the 
outcomes of neoadjuvant chemoradiotherapy or surgery only for 
elderly patients with oesophageal carcinoma were included without 
language restriction. The minimum threshold age used to define the 
elderly was 60 years. The primary outcomes were long-term survival, 
postoperative mortality and complication. All statistical analyses were 
undertaken in Review Manager 5.1 and random effect model was used. 
Results: Out of the initially 144 hits, four studies of 1221 patients (1 
randomized controlled trial, 3 cohort studies) were included. Meta-
analyses based on 3 studies suggested that neoadjuvant 
chemoradiotherapy was not associated with significant improvement 
in disease-free survival (HR=1.08, 95%CI: 0.91-1.28; p=0.38) and 
overall survival (HR=1.12, 95%CI: 0.94-1.33; p=0.19) than surgery 
alone in elderly patients. The 3 years survival rate was 40% vs. 34% in 
neoadjuvant group and surgery alone group, while 5 years survival 
rate was 18% vs. 20%, respectively. No significant survival difference 
was found (p>0.05). And there was also no significantly difference in 
postoperative mortality and major complications (including 
respiratory diseases, cardiovascular diseases, renal failure, and 
anastomotic leak) based on 3 studies. Quality of life was reported in 
one study which showed no significant difference  between two groups 
except for less hospital discharge in neoadjuvant group. 
Conclusions: Comparing with surgery alone, neoadjuvant 
chemoradiotherapy didn't show significantly survival benefit in the 
elderly with oesophageal carcinoma. Though studies were few in 
number, the current available evidence prompted that the elderly 
may get less benefit from neoadjuvant chemoradiotherapy than 
younger. The effect of neoadjuvant chemoradiotherapy for the elderly 
esophageal cancer is still unproven, more clinical studies are needed 
for the definite results.If possible, additional subgroup analysis by 
different ages in randomized controlled trials may help. 
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Purpose/Objective: For several decades, radiotherapy (RT) has been 
widely used to treat metastatic spinal tumors. This study was designed 
to assess the feasibility and early clinical outcome of high dose RT to 
treat such tumors, using helical tomotherapy (HT). 
Materials and Methods: Between June 2009 and December 2011, 51 
sites in 36 patients were treated with high dose RT using HT for spinal 
metastasis. Treatment outcomes and dosimetric analyses of spinal 
cord were retrospectively evaluated.  
Results: Median follow-up was 11.5 months (range, 6–34.6) for 
surviving patients. The median fractional dose and the number of 
fractions in the primary HT arm were 2,700 cGy and 3 fractions, 
respectively. Actuarial 6-month local control rates was 85.7%, and 
symptomatic vertebral compression fractures developed in five 
patients after median 4.2 months. Among 13 patients with 19 
metastatic sites who showed pre-treatment impairment in neurologic 
function, five patients (with seven sites) in whom symptoms were mild 
showed improvement in neuronal function. The median pre-treatment 
VAS score of 7 decreased to a median of 3 after HT (P < 0.001) at 
median 1 month (range, 0.5-3.2). No significant morbidity developed 
during follow-up except for one grade 3 esophagitis.  
Conclusions: The use of HT to treat metastatic spinal tumors appears 
to be both safe and reliable in terms of local tumor control and early 
pain relief. Local progression and the risk of compression fracture in 
patients with pre-existing spinal instability remain as the principal 
factors of limiting improved clinical and functional outcomes. Optimal 
dose fractionation schemes and appropriate patient selections are 
required to achieve better outcomes with high dose RT using HT. 
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Purpose/Objective: Most malignant lymphomas are effectively 
treated by chemotherapy, but some of them relapse and become 
refractory. Treatment of relapsed chemoresistant or refractory 
lymphoma is difficult in many cases and salvage chemotherapy with or 
without autologous stem cell transplant is not always effective. Best 
supportive care is often chosen for such patients; however, palliative 
radiotherapy (RT) is thought to be very useful for some cases. The aim 
of this study was to analyze the treatment outcomes of patients who 
received palliative RT for relapsed or refractory malignant lymphoma. 
Materials and Methods: From 2008-2012, 160 patients with malignant 
lymphoma were treated at the Department of Radiation Oncology in 
our institute. Among them, 20 patients (12.5%) were referred with 
palliative intent, consisting of 17 aggressive lymphomas (13 diffuse 
large B-cell lymphomas and 4 other lymphomas) and 3 indolent 
lymphomas. Six patients had a bulky tumor and 10 patients showed 
multiple masses. The treatment outcomes of palliative RT were 
retrospectively analyzed. 
Results: The median age at the time of RT was 60 years old (range: 
42-92), and 13 patients (65%) were male. Three patients died during 
treatment. The median follow-up from RT was 3 months(range: 0.75-
19). Overall response rate was 94% (complete response: 36%, partial 
response: 58%). The median overall survival was 3 months (range: 
0.75-19). In RT for 48 sites of 20 patients, median dose of treatment 
was 34 Gy (range: 4-50). Nineteen patients (95%) showed a significant 
response to RT (pain relief, prevention of neurological symptoms, 
